Loading
A phase 2 trial of Ramucirumab, Cisplatin, Gemcitabine in metastatic cancer, run by Eli Lilly and Company, active and no longer recruiting.
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer is a phase 2 interventional study registered as NCT02711553 by Eli Lilly and Company, with 309 participants enrolled, started 2016-05-19 and due to reach its primary completion in 2018-02-16. Interventions recorded: Ramucirumab, Merestinib, Cisplatin, Gemcitabine, Placebo Oral. Conditions listed: Biliary Tract Cancer, Metastatic Cancer, Advanced Cancer. Results were posted on ClinicalTrials.gov in 2021; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
309 enrolled.
IQR 3.68 to 8.51; Figures from the ClinicalTrials.gov results section (first posted 2021-02-26), not from a publication · IQR 4.34 to 9.79 · IQR 4.11 to 9.72
SourceIQR 8.48 to 11.76; Figures from the ClinicalTrials.gov results section (first posted 2021-02-26), not from a publication · IQR 11.96 to 16.36 · IQR 11.40 to 15.31
Source95% CI 22.3 to 39.9; Figures from the ClinicalTrials.gov results section (first posted 2021-02-26), not from a publication · 95% CI 11.9 to 27.3 · 95% CI 23.5 to 41.8
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression Free Survival (PFS)primary | 8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | 106 | 6.47 months | - | - | link |
| 80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | 102 | 6.97 months | ||||
| Pooled Placebo | 101 | 6.64 months | ||||
| Overall Survival (OS) | 8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | 106 | 10.45 months | - | - | link |
| 80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | 102 | 14.03 months | ||||
| Pooled Placebo | 101 | 13.04 months | ||||
| Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR): Objective Response Rate (ORR) | 8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | 106 | 31.1% | - | - | link |
| 80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | 102 | 19.6% | ||||
| Pooled Placebo | 101 | 32.7% |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Eli Lilly (incl. Loxo), Gemcitabine, Platinum agents, Monoclonal antibodies.
Shares Ramucirumab, Eli Lilly (incl. Loxo), Gemcitabine, Metastatic cancer (cancer that has spread).
Shares Ramucirumab, Eli Lilly (incl. Loxo), Anti-angiogenic therapy, Monoclonal antibodies.
Shares Ramucirumab, Eli Lilly (incl. Loxo), Anti-angiogenic therapy, Monoclonal antibodies.
Shares Ramucirumab, Anti-angiogenic therapy, Gemcitabine, Monoclonal antibodies.
Shares Ramucirumab, Eli Lilly (incl. Loxo), Anti-angiogenic therapy, Monoclonal antibodies.
Shares Ramucirumab, Anti-angiogenic therapy, Monoclonal antibodies, Cytotoxic chemotherapy.
Shares Ramucirumab, Eli Lilly (incl. Loxo), Anti-angiogenic therapy, Monoclonal antibodies.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/